Solutions with creditors have been achieved and closing in on minimum NOK 25
million in new capital:

Oslo - March 13 2024: SoftOx Solutions, a Medtech and clinical-stage
pharmaceutical company (the "Company"), have reached agreements with bondholders
and employees to convert their total outstanding loan amounts, including accrued
interests and costs, totaling NOK 77 million, to shares in the Company.

Furthermore, the Company is closing in on raising a minimum of NOK 25 million in
equity by making arrangements with administrative suppliers to convert short
term debt of up to NOK 15 million and raising minimum NOK 10 million in new
capital.

When the raise is closed, the company will have fulfilled the requirements set
out in the conditional agreements as described in the stock note of January 24,
2024. The Company thereby summons for an extraordinary general meeting on the
27th of March 2024 at 10.00 am CEST to resolve for a capital increase in the
Company by conversion of debt and contribution of capital, followed by a repair
issue to be held promptly thereafter.

The company have, as described in the stock note of January 11, 2024, elected to
drop down the Skin and Wound care business from the company to a separate
entity. After completion of the drop down, the board will suggest the
distribution of the Skin and Wound Care shares to the shareholders of the SoftOx
Solutions AS as dividend. Existing Shareholders of SoftOx Solutions AS will,
after the distribution, receive one share in the new company for each share
already held in the SoftOx Solutions AS.


For any questions or interview requests, please contact:
Geir Almås, Chair of SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Geir Almås: (+47) 977 59 071

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx) is a Medtech and pharmaceutical company listed on
Euronext Growth Oslo under 'SOFTX'. SoftOx Solutions AS was founded in 2012 and
is headquartered in Oslo. The SoftOx Solutions Group includes: the holding
company SoftOx Solutions AS, the Malmö subsidiary, and subsidiaries SoftOx
Defense Solutions AS and SoftOx Disinfection AS. SoftOx is developing a highly
effective antimicrobial solution for use in biofilm, viral and antimicrobial
resistant infections. The patent-protected technology is based on extensive
research and development in partnership with leading Nordic research institutes.

For more information on SoftOx, visit www.soft-ox.com